phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

Once-Weekly Oral Islatravir Plus Lenacapavir Maintains High Rates of Virologic Suppression in Adults with HIV

A phase 2 randomized study evaluating the efficacy and safety of once-weekly oral islatravir plus lenacapavir (ISL+LEN) in virologically suppressed adults with HIV found that ISL+LEN maintained high rates of virologic suppression through 48 weeks, with no treatment-related grade 3 or greater adverse events or serious adverse events.

December 22, 2025


December 28 2025

December 27 2025

December 26 2025

December 24 2025

December 23 2025

December 22 2025

December 21 2025

December 20 2025

December 19 2025

December 18 2025

December 17 2025

December 16 2025

December 15 2025

Angell Street Psychiatry
Copyright 2025 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy